肝硬化心肌病的发病机制研究进展  

Research progress on the pathogenesis of cirrhotic cardiomyopathy

作　　者：邵震浩 郁志明[1] SHAO Zhenhao;YU Zhiming(Department of Cardiology,the Affiliated Wuxi People′s Hospital of Nanjing Medical University,Wuxi 214023,China)

机构地区：[1]南京医科大学附属无锡市人民医院心血管内科,江苏无锡214023

出　　处：《南京医科大学学报（自然科学版）》2024年第11期1612-1616,共5页Journal of Nanjing Medical University(Natural Sciences)

基　　金：江苏省卫健委老年健康科研课题(LKM2023031);太湖人才计划高端人才项目(2020-THRC-GD-YZM)。

摘　　要：肝硬化心肌病是一种在终末期肝病中出现的心肌功能障碍,它以收缩和舒张功能障碍、心脏结构改变和电生理异常为特征,是一种已知但了解不多的肝硬化并发症,其对肝硬化患者的生存和预后有不良影响。肝功能不全与门静脉高压下的全身炎症反应共同参与其发生发展。文章主要从肝功能不全导致的循环胆汁酸水平升高及门静脉高压下全身慢性炎症反应两方面对近年来肝硬化心肌病发病机制的研究进展进行综述。Cirrhotic cardiomyopathy is a myocardial dysfunction that occurs in end-stage liver disease,characterized by systolic and diastolic dysfunction,cardiac structural changes,and electrophysiological abnormalities.It is a known but poorly understood complication of cirrhosis,with an adverse clinical effect on the overall health,survival,and prognosis of patients with cirrhosis.Liver dysfunction and systemic inflammatory response under portal hypertension are jointly involved in its pathogenesis.This article will review the research progress on the pathogenesis of liver cirrhosis cardiomyopathy in recent years from two aspects:elevated levels of circulating bile acids caused by liver dysfunction and systemic chronic inflammatory response under portal hypertension.

关 键 词：肝硬化心肌病 胆汁酸 门静脉高压 

分 类 号：R575.2[医药卫生—消化系统] R542.2[医药卫生—内科学]